Amfilochiadis Akis A, Backx Peter H, Floras John S
University Health Network and Mount Sinai Hospital Division of Cardiology, Department of Medicine, Canada.
J Hypertens. 2008 Jan;26(1):61-9. doi: 10.1097/HJH.0b013e3282f190cf.
There is increasing evidence that blood coagulation factors can influence blood pressure. In the present study, we tested the hypothesis that the beta fragment of human coagulation factor XIIa (beta-FXIIa) induces adrenal catecholamine-mediated pressor and chronotropic responses via bradykinin generated from the plasma kallikrein-kinin system.
In anaesthetized bioassay rats with blocked autonomic reflexes, in the Brown Norway strain a bolus injection of beta-FXIIa (1 microg/kg, administered intravenously) elicited a 170-fold rise in plasma epinephrine (from 0.12 +/- 0.02 to 20.58 +/- 2.42 nmol/l; P < 0.001) and a fivefold increase in plasma norepinephrine (from 0.11 +/- 0.02 to 0.57 +/- 0.09 nmol/l; P < 0.01), concurrent increases in systolic blood pressure (from 70 +/- 5 to 101 +/- 4 mmHg; P < 0.01) and heart rate (from 315 +/- 11 to 408 +/- 15 bpm; P < 0.01), and a doubling of bradykinin concentrations (P < 0.05). Bilateral adrenal medullectomy abolished both the catecholamine and the haemodynamic responses to beta-FXIIa. Catecholamine, bradykinin and haemodynamic responses to beta-FXIIa were absent in plasma kininogen-deficient Brown Norway Katholiek (BNK) rats. Exogenous bradykinin dose-dependently reproduced these catecholamine and haemodynamic responses in Brown Norway and BNK rats, but not in Brown Norway adrenal medullectomized rats.
The pressor and chronotropic responses to beta-FXIIa in this bioassay preparation are mediated exclusively through adrenal catecholamine release, and require plasma kininogens for their full expression. These observations suggest that interaction between the coagulation, kallikrein-kinin and sympatho-adrenal systems can exert important pressor effects in the absence of counterregulatory autonomic reflexes.
越来越多的证据表明凝血因子可影响血压。在本研究中,我们检验了以下假设:人凝血因子XIIa的β片段(β-FXIIa)通过血浆激肽释放酶-激肽系统产生的缓激肽诱导肾上腺儿茶酚胺介导的升压和变时反应。
在自主反射被阻断的麻醉生物测定大鼠中,在棕色挪威品系中,静脉推注β-FXIIa(1微克/千克)使血浆肾上腺素升高170倍(从0.12±0.02纳摩尔/升升至20.58±2.42纳摩尔/升;P<0.001),血浆去甲肾上腺素增加5倍(从0.11±0.02纳摩尔/升升至0.57±0.09纳摩尔/升;P<0.01),同时收缩压升高(从70±5毫米汞柱升至101±4毫米汞柱;P<0.01),心率加快(从315±11次/分钟升至408±15次/分钟;P<0.01),缓激肽浓度加倍(P<0.05)。双侧肾上腺髓质切除术消除了对β-FXIIa的儿茶酚胺和血流动力学反应。血浆激肽原缺陷的棕色挪威Katholiek(BNK)大鼠对β-FXIIa无儿茶酚胺、缓激肽和血流动力学反应。外源性缓激肽在棕色挪威和BNK大鼠中剂量依赖性地重现了这些儿茶酚胺和血流动力学反应,但在棕色挪威肾上腺髓质切除大鼠中未出现。
在此生物测定制剂中,对β-FXIIa的升压和变时反应完全通过肾上腺儿茶酚胺释放介导,并且其充分表达需要血浆激肽原。这些观察结果表明,在没有反调节自主反射的情况下,凝血、激肽释放酶-激肽和交感-肾上腺系统之间的相互作用可产生重要的升压作用。